Nitazoxanide resources


DRUG INFO
Nitazoxanide

Drug Name: Nitazoxanide

Indication: For the treatment of diarrhea in adults and children caused by the protozoa Giardia lamblia; For the treatment of diarrhea in children caused by the protozoa Cryptosporidium parvum



Pharmacology: Not Available

Mechanism Of Action: The antiprotozoal activity of nitazoxanide is believed to be due to interference with the pyruvate:ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reaction which is essential to anaerobic energy metabolism. Studies have shown that the PFOR enzyme from Giardia lamblia directly reduces nitazoxanide by transfer of electrons in the absence of ferredoxin. The DNA-derived PFOR protein sequence of Cryptosporidium parvum appears to be similar to that of Giardia lamblia. Interference with the PFOR enzyme-dependent electron transfer reaction may not be the only pathway by which nitazoxanide exhibits antiprotozoal activity.

Drug Category: Antiparasitics

Brand Names/Synonyms: Alinia; BRN 1225475; DRG-0242; NITAZOXANIDE; Nitazoxanid; Nitazoxanida [Inn-Spanish]; Nitazoxanide; Nitazoxanide Metabolite; Nitazoxanide [Usan:Inn]; Nitazoxanidum [Inn-Latin]; Tizoxanide Glucuronide

Dosage Forms: Oral suspension; Tablet

Absorption: 70%

Interactions: DrugBank: Interactions for Nitazoxanide

Interactions for Nitazoxanide:


Tizoxanide is highly bound to plasma protein (>99.9%). Therefore, caution should be used when administering nitazoxanide concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., warfarin). In vitro metabolism studies have demonstrated that tizoxanide has no significant inhibitory effect on cytochrome P450 enzymes. Although no drug-drug interaction studies have been conducted in vivo, it is expected that no significant interaction would occur when nitazoxanide is co-administered with drugs that either are metabolized by or inhibit cytochrome P450 enzymes.





Chemical IUPAC Name: [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate

Chemical Formula: C12H9N3O5S

Half Life: Not Available

Drug Type: Approved Drug

# Accession No: APRD00558

CAS Registry Number: 55981-09-4



Nitazoxanide News
(When available)


Romark to Develop Alinia (nitazoxanide) as New Treatment for ...  Jan 10, 2006
PharmaLive.com (press release), 10, 2006 /PRNewswire/ -- Romark Laboratories announced that it is initiating US clinical development of Alinia(R) (nitazoxanide) tablets for treating chronic ...

Romark Laboratories to Develop Alinia as New Treatment for Chronic ...  Jan 10, 2006
EndoNurse, TAMPA, Fla. -- Romark Laboratories announced that it is initiating US clinical development of Alinia (nitazoxanide) tablets for treating chronic hepatitis C. ...

(PRN) - CYIOS Corporation Announces Record Quarterly and Annual ...  Jan 10, 2006
Bolsamania.com, Awards ... [+. PRN) - Romark to Develop Alinia(R) (nitazoxanide) as New Treatment for Chronic Hepatitis C ... [+. PRN) - Spartan ...

Rifle girls net season’s first win while on the road  Dec 13, 2005
Glenwood Springs Post Independent, ...three minutes to play. The game’s final dramatics were set up after Alinia Brennan and Aspen Peppel hit field goals. Up 64-63 ...


Home Copyright phasechange.org 2006.
All Rights Reserved.
Google
 
Web rxreview.org